2017年9月
Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer
ANTICANCER RESEARCH
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 37
- 号
- 9
- 開始ページ
- 4979
- 終了ページ
- 4986
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.21873/anticanres.11909
- 出版者・発行元
- INT INST ANTICANCER RESEARCH
Background/Aim: Pancreatobiliary cancer is a disease associated with a dismal prognosis and limited treatment options. The aim of the present study was to clarify the usefulness of circulating galectin-3 in pancreatobiliary cancer. Patients and Methods: We examined serum galectin3 concentrations in 45 patients with pancreatobiliary cancer. Receiver operating characteristic curves were utilized to evaluate the accuracy of circulating galectin-3 to discriminate pancreatobiliary cancer patients from controls and predict the prognostic outcomes. Results: Circulating galectin-3 had diagnostic value at the cut-off level of 6.2 ng/ml, and the patients' overall survival was predictable at the cut-off level of 10.3 ng/ml. Furthermore, circulating galectin-3 >= 10.3 ng/ml was an independent prognostic marker in pancreatobiliary cancer. Regarding biliary cancer, higher galectin-3 was associated with malnutrition. On the other hand, regarding pancreatic cancer, higher galectin-3 levels were associated with higher inflammatory parameters. Conclusion: Galectin-3 can be a useful biomarker in patients with pancreatobiliary cancer.
- リンク情報
- ID情報
-
- DOI : 10.21873/anticanres.11909
- ISSN : 0250-7005
- eISSN : 1791-7530
- PubMed ID : 28870921
- Web of Science ID : WOS:000412578200032